Verteporfin (CAS 129497-78-5)
See product citations (5)
QUICK LINKS
Verteporfin is a lipophilic, water-soluble compound utilized in scientific research. Functioning as a photosensitizer, it specifically targets and eradicates abnormal blood vessels within the macula, the central region of the retina. Verteporfin initiates a photodynamic reaction upon exposure to light, leading to the destruction of these abnormal vessels. This reaction could possibly alleviate macular inflammation and enhance vision. By generating reactive oxygen species (ROS) through a photochemical reaction, verteporfin effectively reacts with the abnormal blood vessels, resulting in their eradication. Beyond its anti-inflammatory properties, verteporfin exhibits biochemical and physiological effects in vitro. Notably, it diminishes levels of vascular endothelial growth factor (VEGF), a protein involved in new blood vessel formation, thereby curtailing their development. Additionally, verteporfin reduces nitric oxide levels, which plays a role in blood flow regulation.
Verteporfin (CAS 129497-78-5) References
- Verteporfin inhibits lipopolysaccharide-induced inflammation by multiple functions in RAW 264.7 cells. | Wang, Y., et al. 2020. Toxicol Appl Pharmacol. 387: 114852. PMID: 31812773
- Verteporfin Inhibits PD-L1 through Autophagy and the STAT1-IRF1-TRIM28 Signaling Axis, Exerting Antitumor Efficacy. | Liang, J., et al. 2020. Cancer Immunol Res. 8: 952-965. PMID: 32265228
- YAP/TAZ Transcriptional Coactivators Create Therapeutic Vulnerability to Verteporfin in EGFR-mutant Glioblastoma. | Vigneswaran, K., et al. 2021. Clin Cancer Res. 27: 1553-1569. PMID: 33172899
- Preventing Engrailed-1 activation in fibroblasts yields wound regeneration without scarring. | Mascharak, S., et al. 2021. Science. 372: PMID: 33888614
- Anti-invasive efficacy and survival benefit of the YAP-TEAD inhibitor verteporfin in preclinical glioblastoma models. | Barrette, AM., et al. 2022. Neuro Oncol. 24: 694-707. PMID: 34657158
- Melatonin and verteporfin synergistically suppress the growth and stemness of head and neck squamous cell carcinoma through the regulation of mitochondrial dynamics. | Shin, YY., et al. 2022. J Pineal Res. 72: e12779. PMID: 34826168
- Verteporfin-loaded supramolecular micelles for enhanced cisplatin-based chemotherapy via autophagy inhibition. | Ye, J., et al. 2022. J Mater Chem B. 10: 2670-2679. PMID: 35043820
- Verteporfin is a substrate-selective γ-secretase inhibitor that binds the amyloid precursor protein transmembrane domain. | Castro, MA., et al. 2022. J Biol Chem. 298: 101792. PMID: 35247387
- Verteporfin synergizes the efficacy of anti-PD-1 in cholangiocarcinoma. | Fu, J., et al. 2022. Hepatobiliary Pancreat Dis Int. 21: 485-492. PMID: 35307294
- The Role of Verteporfin in Prevention of Periprosthetic Capsular Fibrosis: An Experimental Study. | Yi, Z., et al. 2022. Aesthet Surg J. 42: 820-829. PMID: 35420670
- Verteporfin Inhibits the Progression of Spontaneous Osteosarcoma Caused by Trp53 and Rb1 Deficiency in Ctsk-Expressing Cells via Impeding Hippo Pathway. | Li, Y., et al. 2022. Cells. 11: PMID: 35456040
- Verteporfin protects against Th17 cell-mediated EAE independently of YAP inhibition. | Brosinsky, P., et al. 2022. Eur J Immunol. 52: 1523-1526. PMID: 35776890
- Anticancer effect of verteporfin on non-small cell lung cancer via downregulation of ANO1. | Jeong, SB., et al. 2022. Biomed Pharmacother. 153: 113373. PMID: 35785700
- In-Vitro Use of Verteporfin for Photodynamic Therapy in Glioblastoma. | Jeising, S., et al. 2022. Photodiagnosis Photodyn Ther. 40: 103049. PMID: 35932958
- Verteporfin inhibits the dedifferentiation of tubular epithelial cells via TGF-β1/Smad pathway but induces podocyte loss in diabetic nephropathy. | Qi, C., et al. 2022. Life Sci. 311: 121186. PMID: 36375573
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Verteporfin, 10 mg | sc-475698 | 10 mg | $354.00 | |||
Verteporfin, 100 mg | sc-475698A | 100 mg | $2764.00 |